| Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report P Horby, WS Lim, J Emberson, M Mafham, J Bell, L Linsell, N Staplin, ... MedRxiv, 2020.06. 22.20137273, 2020 | 11432* | 2020 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5252 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2746 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1649 | 2020 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 1457 | 2020 |
| Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children SL Weiss, MJ Peters, W Alhazzani, MSD Agus, HR Flori, DP Inwald, ... Intensive care medicine 46, 10-67, 2020 | 1357 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1321 | 2021 |
| Dysfunction of endothelial protein C activation in severe meningococcal sepsis SN Faust, M Levin, OB Harrison, RD Goldin, MS Lockhart, S Kondaveeti, ... New England Journal of Medicine 345 (6), 408-416, 2001 | 876 | 2001 |
| Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ... The Lancet 396 (10259), 1345-1352, 2020 | 791 | 2020 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 771* | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 733 | 2021 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 659 | 2021 |
| Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study TI Coulter, A Chandra, CM Bacon, J Babar, J Curtis, N Screaton, ... Journal of Allergy and Clinical Immunology 139 (2), 597-606. e4, 2017 | 596 | 2017 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 485 | 2021 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 466 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 437* | 2021 |
| Role of coagulation inhibitors in inflammation CT Esmon Thrombosis and haemostasis 86 (07), 51-56, 2001 | 396 | 2001 |
| A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process R Harwood, B Allin, CE Jones, E Whittaker, P Ramnarayan, AV Ramanan, ... The Lancet Child & Adolescent Health 5 (2), 133-141, 2021 | 364 | 2021 |
| Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the european society for immunodeficiencies-activated phosphoinositide 3-kinase δ … ME Maccari, H Abolhassani, A Aghamohammadi, A Aiuti, O Aleinikova, ... Frontiers in immunology 9, 543, 2018 | 345 | 2018 |
| Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial RC Read, D Baxter, DR Chadwick, SN Faust, A Finn, SB Gordon, ... The Lancet 384 (9960), 2123-2131, 2014 | 303 | 2014 |
michael LevinProfessor of International Child Health Imperial College LondonVerified email at imperial.ac.uk
